Fierce Pharma September 13, 2024
Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals and sales.
But a group of Harvard researchers has found another way to measure the impact individual drugmakers have had in bringing oncology treatments to the market—by assessing the clinical value of their new approvals.
Using a scoring system established a decade ago by the European Society of Medical Oncology (ESMO) to identify which approvals provide the highest clinical benefit, the researchers sorted the results by company. The scoring system is called the ESMO-Magnitude of Clinical Benefit Scale (MCBS).
Drugmakers at the top of the list were Astellas, AstraZeneca, Daiichi Sankyo, Gilead Sciences and Novartis. The five companies accounted...
Today's Sponsors
Today's Sponsor